SCHEMBL4228593

SCHEMBL4228593

CCCCN1CCC(N(C)c2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)c(F)c4)cc3)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
HRH3 Q9Y5N1 2/20 0.39
UBE2M P61081 5/20 0.39
DCUN1D1 Q96GG9 5/20 0.39
FLT1 P17948 2/20 0.38
FLT4 P35916 2/20 0.38
KDR P35968 2/20 0.38
SLC6A5 Q9Y345 1/20 0.37
RAF1 P04049 1/20 0.36
MAPT P10636 3/20 0.36
TSHR P16473 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
RAB9A P51151 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4689011 0.91 PKM (0.40) PKMRAF1MAPTHSD17B10TAS1R3
SCHEMBL4232419 0.90 TAS1R3 (0.39) PKMUBE2MDCUN1D1FLT1FLT4
SCHEMBL4236370 0.88 PKM (0.41) PKMHRH3FLT1FLT4KDR
SCHEMBL4228587 0.87 PKM (0.40) PKMHRH3FLT1FLT4KDR
SCHEMBL4683906 0.85 KDR (0.36) UBE2MDCUN1D1FLT1FLT4KDR
SCHEMBL4237921 0.85 CCR3 (0.41) PKMHRH3FLT1FLT4KDR
SCHEMBL4236573 0.84 MCHR1 (0.45) PKMKDRRAF1MAPTTAS1R3
SCHEMBL4240513 0.84 MCHR1 (0.40) PKMUBE2MDCUN1D1SLC6A5MAPT
SCHEMBL4233470 0.83 MCHR1 (0.40) PKMHRH3FLT1FLT4KDR
SCHEMBL4240272 0.82 LMNA (0.42) FLT1FLT4KDRMAPTTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885HRH3 210/4885UBE2M 4675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.